vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and VINCE HOLDING CORP. (VNCE). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $85.1M, roughly 2.0× VINCE HOLDING CORP.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 6.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 6.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
VINCE. is a contemporary clothing fashion brand founded in 2002. In 2023 Authentic Brands Group purchased its intellectual property in a $76.5 million deal.
ESPR vs VNCE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $85.1M |
| Net Profit | — | $2.7M |
| Gross Margin | — | 49.2% |
| Operating Margin | 50.6% | 6.4% |
| Net Margin | — | 3.2% |
| Revenue YoY | 143.7% | 6.2% |
| Net Profit YoY | — | -37.3% |
| EPS (diluted) | $0.32 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $85.1M | ||
| Q3 25 | $87.3M | $73.2M | ||
| Q2 25 | $82.4M | $57.9M | ||
| Q1 25 | $65.0M | $80.0M | ||
| Q4 24 | $69.1M | $80.2M | ||
| Q3 24 | $51.6M | $74.2M | ||
| Q2 24 | $73.8M | $59.2M | ||
| Q1 24 | $137.7M | $75.3M |
| Q4 25 | — | $2.7M | ||
| Q3 25 | $-31.3M | $12.1M | ||
| Q2 25 | $-12.7M | $-4.8M | ||
| Q1 25 | $-40.5M | $-28.3M | ||
| Q4 24 | — | $4.3M | ||
| Q3 24 | $-29.5M | $569.0K | ||
| Q2 24 | $-61.9M | $4.4M | ||
| Q1 24 | $61.0M | $-4.7M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 50.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 50.1% | ||
| Q4 24 | — | 50.0% | ||
| Q3 24 | — | 47.4% | ||
| Q2 24 | — | 50.6% | ||
| Q1 24 | — | 45.4% |
| Q4 25 | 50.6% | 6.4% | ||
| Q3 25 | -11.4% | 15.2% | ||
| Q2 25 | 8.6% | -7.7% | ||
| Q1 25 | -34.0% | -37.1% | ||
| Q4 24 | -6.4% | 7.2% | ||
| Q3 24 | -31.0% | 1.5% | ||
| Q2 24 | 3.5% | 9.5% | ||
| Q1 24 | 52.5% | -2.2% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | -35.9% | 16.5% | ||
| Q2 25 | -15.4% | -8.3% | ||
| Q1 25 | -62.2% | -35.5% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | -57.2% | 0.8% | ||
| Q2 24 | -83.9% | 7.4% | ||
| Q1 24 | 44.3% | -6.2% |
| Q4 25 | $0.32 | $0.21 | ||
| Q3 25 | $-0.16 | $0.93 | ||
| Q2 25 | $-0.06 | $-0.37 | ||
| Q1 25 | $-0.21 | $-2.25 | ||
| Q4 24 | $-0.14 | $0.34 | ||
| Q3 24 | $-0.15 | $0.05 | ||
| Q2 24 | $-0.33 | $0.35 | ||
| Q1 24 | $0.34 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $53.4M |
| Total Assets | $465.9M | $246.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $1.1M | ||
| Q3 25 | $92.4M | $777.0K | ||
| Q2 25 | $86.1M | $2.6M | ||
| Q1 25 | $114.6M | $607.0K | ||
| Q4 24 | $144.8M | $892.0K | ||
| Q3 24 | $144.7M | $711.0K | ||
| Q2 24 | $189.3M | $739.0K | ||
| Q1 24 | $226.6M | $357.0K |
| Q4 25 | $-302.0M | $53.4M | ||
| Q3 25 | $-451.4M | $49.3M | ||
| Q2 25 | $-433.5M | $37.2M | ||
| Q1 25 | $-426.2M | $41.8M | ||
| Q4 24 | $-388.7M | $57.1M | ||
| Q3 24 | $-370.2M | $52.4M | ||
| Q2 24 | $-344.2M | $51.7M | ||
| Q1 24 | $-294.3M | $47.2M |
| Q4 25 | $465.9M | $246.0M | ||
| Q3 25 | $364.0M | $239.0M | ||
| Q2 25 | $347.1M | $218.0M | ||
| Q1 25 | $324.0M | $222.7M | ||
| Q4 24 | $343.8M | $254.7M | ||
| Q3 24 | $314.1M | $253.6M | ||
| Q2 24 | $352.3M | $223.1M | ||
| Q1 24 | $373.1M | $225.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-5.1M |
| Free Cash FlowOCF − Capex | — | $-5.7M |
| FCF MarginFCF / Revenue | — | -6.7% |
| Capex IntensityCapex / Revenue | 0.0% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -1.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-5.1M | ||
| Q3 25 | $-4.3M | $4.2M | ||
| Q2 25 | $-31.4M | $-11.8M | ||
| Q1 25 | $-22.6M | $22.7M | ||
| Q4 24 | $-35.0M | $6.4M | ||
| Q3 24 | $-35.3M | $-3.2M | ||
| Q2 24 | $-7.2M | $-3.9M | ||
| Q1 24 | $53.8M | $14.8M |
| Q4 25 | — | $-5.7M | ||
| Q3 25 | — | $2.1M | ||
| Q2 25 | — | $-13.2M | ||
| Q1 25 | — | $21.2M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $-35.5M | $-3.9M | ||
| Q2 24 | $-7.3M | $-4.6M | ||
| Q1 24 | $53.8M | $14.2M |
| Q4 25 | — | -6.7% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | -22.9% | ||
| Q1 25 | — | 26.5% | ||
| Q4 24 | — | 6.4% | ||
| Q3 24 | -68.7% | -5.2% | ||
| Q2 24 | -9.9% | -7.8% | ||
| Q1 24 | 39.0% | 18.9% |
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 1.6% | ||
| Q3 24 | 0.3% | 0.9% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.1% | 0.7% |
| Q4 25 | — | -1.86× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | -5.61× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
VNCE
| Vince Wholesale | $52.0M | 61% |
| Vince Direct To Consumer | $33.1M | 39% |
